课题基金 / 基金详情

Reliable evaluation of associations between Lp-PLA2 markers and the risk of cardiovascular outcomes

Reliable evaluation of associations between Lp-PLA2 markers and the risk of cardiovascular outcomes
Lp-PLA2 标记物与心血管结局风险之间关联的可靠评估
批准号:
G0601284/1
负责人:
John Danesh
金额:
$39.65万
依托单位:
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2007
资助国家:
英国
项目状态:
已结题
起止时间:
2007 至 --

项目摘要

项目成果

John Danesh的其他基金

相似基金

相关文献

中文摘要
翻译
在英国和世界范围内,心脏病仍然是导致死亡和残疾的主要原因。控制心脏病的已知原因(如吸烟、高血压和胆固醇水平升高)可以大大降低患病风险。这一成功鼓励了对可能进一步降低风险的新原因的探索,特别是如果像血液胆固醇水平一样,测量或改变它们可以改善疾病预测或预防。一种叫做Lp-PLA2的血液酶(?脂蛋白相关磷脂酶A2)可能在心脏狭窄中起直接作用。并引发心脏病。最近有几项研究报道了血液中Lp-PLA2的数量(或活性)与随后的心脏病风险之间的正相关。最近已经发明了几乎完全阻断Lp-PLA2(在循环血液和动脉中)活性的新药,并正在进行早期试验。2004年,美国食品和药物管理局批准使用一种测量血液中Lp-PLA2水平的测试(称为PLAC)。但是这种测试并没有被广泛采用,因为它还不可靠地知道Lp-PLA2的测量是否(或在多大程度上)可以在心脏病发作的早期检测中导致有用的改进。目前还不清楚在不同情况下,血液中Lp-PLA2的水平与未来心脏病发作的发生有多大程度的关联,比如在最初健康的成年人中与有心脏病或中风病史的患者进行比较。这些信息对于规划lp - pla2抑制药物的大型试验非常重要。为了帮助回答这些问题和其他关键问题,我们将汇集至少27项长期医学调查的原始数据,这些调查已经记录了总计约75,000人的初始Lp-PLA2水平,其中约15,000人自监测以来患上了心脏病或中风。这个独特的数据库将涵盖几乎整个世界。l - pla2水平与心血管疾病的流行病学知识。对它的分析将迅速产生精确、全面和可靠的发现,这将有助于确定:(i) Lp-PLA2测量是否值得纳入心脏病的常规筛查测试;(ii)在大型试验中测试新的Lp-PLA2抑制药物的最佳方法(例如,可能需要多少人?)初始特征是什么?)
英文摘要
Heart attacks remain leading causes of death and disability in the UK and worldwide. Controlling known causes of heart disease (such as smoking, high blood pressure and raised cholesterol levels) substantially cuts the risk of disease. This success has encouraged the search for new causes which might further reduce risk, particularly if, like blood cholesterol levels, measuring or changing them can lead to improvements in disease prediction or prevention.A blood enzyme known as Lp-PLA2 (?lipoprotein-associated phospholipase A2?) may play a direct role in narrowing the heart?s arteries and triggering heart attacks. Several studies have recently reported positive correlations between the amount (or activity) of Lp-PLA2 in the bloodstream and subsequent risk of heart disease. New medicines which almost completely block the activity of Lp-PLA2 (both in circulating blood and in arteries) have recently been invented and are being tested in early trials. In 2004 the US Food and Drug Administration approved for use a test (known as ?PLAC?) which measures blood levels of Lp-PLA2. But this test has not been widely adopted because it is not yet reliably known whether (or to what extent) Lp-PLA2 measurements can lead to useful improvements in the early detection of heart attacks. It is also not clear to what extent blood levels of Lp-PLA2 are correlated with the future occurrence of heart attacks in different situations, such as in initially healthy adults compared with patients who have a history of heart disease or stroke. Such information is important in planning large trials of Lp-PLA2-inhibiting medicines.To help provide answers to these and other key questions, we will pool original data from at least 27 long-term medical surveys which have already recorded initial Lp-PLA2 levels in a total of about 75,000 individuals, of whom about 15,000 have developed heart disease or strokes since monitoring. This unique database will encompass almost the entirety of the world?s available epidemiological knowledge on Lp-PLA2 levels and cardiovascular diseases. Analyses of it will rapidly yield precise, comprehensive and reliable findings that will help to determine: (i) whether or not Lp-PLA2 measurement merits incorporation into routine screening tests for heart disease and (ii) the best way to test new Lp-PLA2-inhibiting medicines in large trials (eg, how many people are likely to be required? with what initial characteristics?).
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Molecules to Health Records
  • 批准号:
    HDR-23007
  • 项目类别:
    Intramural
  • 资助金额:
    $762.35万
  • 财政年份:
    2023
  • 负责人:
    John Danesh
  • 依托单位:
Building a comprehensive aortic aneurysm and dissection prediction model incorporating genetic and non-genetic factors
  • 批准号:
    MR/T023783/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $34.79万
  • 财政年份:
    2019
  • 负责人:
    John Danesh
  • 依托单位:
Cambridge Alliance to Protect Bangladesh from Long-term Environmental Hazards (CAPABLE)
  • 批准号:
    MR/P02811X/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $1036.46万
  • 财政年份:
    2017
  • 负责人:
    John Danesh
  • 依托单位:
Large-scale integrative studies of risk factors in coronary heart disease: from discovery to application
  • 批准号:
    MR/L003120/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $257.11万
  • 财政年份:
    2013
  • 负责人:
    John Danesh
  • 依托单位:
国内基金
海外基金
新型小分子蛋白—人肝细胞生长因子三环域(hHGFK1)抑制破骨细胞及治疗小鼠骨质疏松的疗效评估与机制研究
  • 批准号:
    82370885
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    姚晨
  • 依托单位:
基于重要农地保护LESA(Land Evaluation and Site Assessment)体系思想的高标准基本农田建设研究
  • 批准号:
    41340011
  • 项目类别:
    专项基金项目
  • 资助金额:
    20.0万元
  • 批准年份:
    2013
  • 负责人:
    钱凤魁
  • 依托单位:
基于观测角度的汉语名词性隐喻逻辑释义和评价方法研究
  • 批准号:
    61075058
  • 项目类别:
    面上项目
  • 资助金额:
    25.0万元
  • 批准年份:
    2010
  • 负责人:
    苏畅
  • 依托单位:
面向认知网络的自律计算模型及评价方法研究
  • 批准号:
    60973027
  • 项目类别:
    面上项目
  • 资助金额:
    30.0万元
  • 批准年份:
    2009
  • 负责人:
    王慧强
  • 依托单位: